 |
인쇄하기
취소
|
Kuhnil to complete health registration of Omacor for hyperlipidemia.
Kuhnil announced that the KFDA registration of Omacor (omega-3 fatty acid ethylester) was completed for the treatment of hyperlipidemia.
Omacor was originally developed by Pronova in Norway, approved very recently by the U. S. FDA as a prescription drug for the treatment of hyperlimpidemia and a secondary preventive medication for the patients after heart attack.
Kuhnil said that a clin...
Omacor was originally developed by Pronova in Norway, approved very recently by the U. S. FDA as a prescription drug for the treatment of hyperlimpidemia and a secondary preventive medication for the patients after heart attack.
Kuhnil said that a clin...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.